Advanced Colorectal Carcinoma Clinical Trial
Official title:
Survival Benefit of Compound Kushen Injection in Treatment of Advanced Colorectal Cancer Based on Real World Registration Platform
To clarify the effectiveness and safety of compound kushen injection in the treatment of advanced colorectal cancer.
This study include a multi-center, randomized, parallel controlled clinical trial.The randomized clinical trial will enroll approximately 318 patients. Participants will be randomly divided into experimental (n=159) and control groups (n=159).Patients in the experimental group was treated with palliative care group first-line scheme + compound kushen injection. Patients in the control group will receive palliative care group first-line scheme.The primary endpoint is PFS. The research protocol was approved by the relevant ethics committees, and the study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. Patients gave written informed consent to participate in the trial. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04582981 -
Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04164069 -
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
|
Phase 1 | |
| Terminated |
NCT05648006 -
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04771715 -
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
|
||
| Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02983578 -
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT01208194 -
Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05967533 -
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
|
Phase 1 | |
| Recruiting |
NCT04705818 -
Combining Epigenetic And Immune Therapy to Beat Cancer.
|
Phase 2 | |
| Not yet recruiting |
NCT05883683 -
Molecular Study and Precision Medicine for Colorectal Cancer
|
||
| Recruiting |
NCT05759923 -
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
|
Phase 1 | |
| Completed |
NCT01277406 -
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT04645797 -
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
|
Phase 1 | |
| Recruiting |
NCT05406206 -
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT04109924 -
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
|
Phase 2 | |
| Recruiting |
NCT04704661 -
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
|
Phase 1 | |
| Recruiting |
NCT05969860 -
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
|
Phase 2 | |
| Recruiting |
NCT05200442 -
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00499850 -
Phase I FOLFOX Combination
|
Phase 1 | |
| Active, not recruiting |
NCT04535401 -
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
|
Phase 1 |